Cargando…
Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
OBJECTIVE: To estimate the incidence of major adverse cardiovascular events (MACE) with genotype test-guided antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome. METHODS: Patients who had undergone PCI for acute coronary syndrome as well a...
Autores principales: | Ramesh, S., Socrates, S., Rajasekaran, M.A., Senguttuvan, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772580/ https://www.ncbi.nlm.nih.gov/pubmed/33357650 http://dx.doi.org/10.1016/j.ihj.2020.09.002 |
Ejemplares similares
-
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
por: Deiman, B. A. L. M., et al.
Publicado: (2016) -
CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
por: Stys, Tomasz P., et al.
Publicado: (2021) -
Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018) -
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All‐Cause Mortality in Clinical Trials of Time‐Constrained Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention
por: McClure, John D., et al.
Publicado: (2020) -
Individualized intensified antiplatelet therapy based on platelet reactivity testing reduces the incidence of cardiovascular events in patients undergoing percutaneous coronary intervention
por: Spartalis, Michael, et al.
Publicado: (2017)